C92.31Myeloid sarcoma, in remission

C92.31 is the ICD-10-CM diagnosis code for myeloid sarcoma, in remission. It belongs to category C92 (myeloid leukemia), block C81-C96 (malignant neoplasms of lymphoid, hematopoietic and related tissue) and chapter 2 (neoplasms). It is billable, so it can be reported on its own for dates of service from October 1, 2026 through September 30, 2027.

Within C92.3 (myeloid sarcoma), C92.31 is specifically for myeloid sarcoma, in remission. Related codes cover not having achieved remission (C92.30) and in relapse (C92.32).

As a secondary diagnosis it is a CC (complication or comorbidity), which can move an inpatient stay into the "with CC" MS-DRG of its family, unless the principal diagnosis excludes it.

In MS-DRG v44.0, it is part of the grouping logic for DRG 820 (Lymphoma and Leukemia with Major O.R. Procedures with MCC, relative weight 6.2481), DRG 821 (Lymphoma and Leukemia with Major O.R. Procedures with CC, relative weight 2.2023), DRG 822 (Lymphoma and Leukemia with Major O.R. Procedures without CC/MCC, relative weight 1.1272), DRG 823 (Lymphoma and Non-Acute Leukemia with Other Procedures with MCC, relative weight 4.6059), DRG 824 (Lymphoma and Non-Acute Leukemia with Other Procedures with CC, relative weight 2.2515), DRG 825 (Lymphoma and Non-Acute Leukemia with Other Procedures without CC/MCC, relative weight 1.2995) and 3 more, in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms), as a principal or secondary diagnosis. The DRG a claim lands in depends on the principal diagnosis, procedures and any CC/MCC secondary diagnoses.

It has been part of ICD-10-CM since the code set took effect on October 1, 2015 and hasn't changed since.

Before ICD-10, this condition was coded in ICD-9-CM as 205.31 (myeloid sarcoma, in remission).